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Abstract
Care of patients with proton therapy has increased in the past decade. It is 
important to report on outcomes and disease specific utilization of particle therapy. 
In this chapter, we review our experience in developing a registry for pediatric 
patients treated with radiation to assess outcomes and provide a platform for shared 
research interests.
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1. Introduction
Pediatric cancers comprise a simultaneously rare but highly varied cadre of 
diseases. They account for less than 1% of all new cancer diagnoses made in the 
United States each year with nearly 17,000 projected in 2020 for patients under 
20 years of age [1]. These can be classified as liquid tumors (leukemias and lympho-
mas) and solid tumors originating in central nervous system (CNS) and non-CNS 
sites. While many patients undergo radiotherapy (RT) as part of standard disease 
management, a significant portion of treatment paradigms does not include RT 
outright or requires RT to the entire body (e.g. total body irradiation in conditioning 
for stem cell transplants in patients with leukemia), thereby obviating the need for 
highly technical delivery methods such as proton radiotherapy (PRT). The number 
of patients available for study, therefore, is substantially less such that studying 
treatment outcomes is challenging and limits the ability of any one radiation center 
to amass clinical data and generate timely empirical results.
Survival and toxicity outcomes associated with PRT, as with photon radio-
therapy (XRT), can be obtained through inquiries ranging in quality from single-
institution retrospective studies to prospective randomized phase three clinical 
trials. However, in the pediatric population, randomized trials are not feasible given 
lack of equipoise among parents of patients and caregivers between proton- and 
photon-based radiation. In addition, low disease prevalence, varied disease man-
agement options, and varied anatomic sites can result in limited data availability. 
Consequently, collaboration among institutions is needed to obtain a critical mass 
of data that enables meaningful outcomes research. Children’s Oncology Group 
(COG) and the International Society of Pediatric Oncology (SIOP) are cooperative 
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groups that work together to try to answer critical treatment-related questions 
on the more common pediatric malignancies. However, access to cooperative 
group data for ad hoc studies is limited, even among cooperative group members. 
Furthermore, these groups are focused on primary disease-specific endpoints and 
typically do not prioritize the collection of data on health outcomes and morbidity 
that can affect health-related quality of life. Importantly, COG has a registry called 
Project:EveryChild that attempts to capture limited information and biological 
specimens on all patients with a pediatric malignancy or benign tumor. However, 
the only information collected on RT is whether a patient was treated with it but no 
information on dose, site, timing of radiotherapy, or other factors that can play a 
role in disease control and other health outcomes [2].
To address these challenges, the Pediatric Proton/Photon Consortium Registry 
(PPCR) was initiated in 2010 [3–5], first focusing exclusively on studying clinical 
outcomes after PRT. Herein we describe the PPCR’s administrative structure and 
processes, collected data (including patient demographics), and our vision for how 
the PPCR may further evolve.
2. PPCR overview
The PPCR is a consented registry established by and centrally coordinated 
through a team at Massachusetts General Hospital (MGH). Nineteen institutions 
are currently contributing data while 11 are in the process of joining [6]. Pediatric 
patients treated with radiation prior to 22 years of age are offered enrollment and 
all treatment exposures and baseline patient health and tumor characteristics 
are collected. The registry also tracks survival and treatment-related toxicity for 
all and patient-reported quality-of-life (PedsQL) data on a voluntary basis at 14 
institutions. The PPCR enrolled its first participant in October, 2012 and was 
initially designed to collect data on the pediatric proton cohort. Then in 2018, after 
input from the National Cancer Institute (NCI) and various stakeholders, patients 
treated with any radiation modality became eligible to enroll. The PPCR was jointly 
funded by the NCI/MGH Federal Share of Proton Income research fund until 2019 
and is now funded predominantly through MGH research funds and philanthropic 
donations.
2.1 Site acquisition
All radiation centers that treat pediatric patients are welcome to join, although 
current laws hinder some centers from joining among those based outside the 
United States, Canada, and Australia. Once clinicians at an institution express 
interest in participating, they are provided the current protocol, informed con-
sent form, financial disclosure form, signature and delegation of responsibilities 
logs, and investigator agreement. The interested investigator(s) will then begin 
the regulatory proceedings needed to open the study at their institution. Unlike 
involvement in other registries and cooperative groups, there is no central cost to 
join though institutions are responsible for supporting the staff needed to com-
plete study-related tasks.
2.2 Team composition
The coordinating team at MGH consists of five individuals: principal investiga-
tor (PI), project manager, biostatistician, and two clinical research coordinators 
(CRC). The coordinating team is responsible for central registry oversight and 
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reporting, patient registration, database management, monitoring, and quality 
assurance. Individual site team composition is dependent on available resources and 
ranges from a single physician up to a staff of eight. Notably, limited institutional 
resources is the most commonly reported barrier to participation.
2.3 Regulatory structure
Each site uses its own Institutional Review Board (IRB) and abides by its own 
institutional regulations. The site’s protocol and consent forms are approved by 
the coordinating team at MGH. Eight centers use the Western Institutional Review 
Board, Inc., in lieu of a local IRB. To streamline ongoing review and protocol 
changes, the coordinating team compiles study changes into a single annual amend-
ment submission that is implemented study-wide.
2.4 Consent and enrollment
All children and young adults (<22 years of age) who receive radiation at one of 
our participating institutions are eligible and invited to enroll. For this minimal-
risk study, informed consent may be obtained by any member of the study team 
(e.g. CRC, research nurse, advanced practice provider, physician/PI) and must 
be obtained prior to completing any study-related procedures. Most patients are 
enrolled at some point during their primary treatment, although prior radiation 
treatment does not exclude them from being eligible. PedsQL study consent is 
sought in the first week of treatment to facilitate timely completion of the baseline 
survey. All patients are centrally registered at the coordinating center and assigned 
a study identification number (SIDN). The registry’s goal is to capture all pediatric 
patients treated with RT. However, some patients decline to enroll, which can 
introduce bias in the collected data. To mitigate this effect, basic, non-identifying 
demographic information is gathered on patients who decline to participate, 
including their reason for doing so. This facilitates identifying barriers to registry 
enrollment and meaningful disparities between participants and patients who do 
not consent. Participants remain on study until death, withdrawal of consent, or 
study termination.
2.5 Data infrastructure and collection
Clinical data and patient-reported outcomes are collected and managed using 
the REDCap platform available through the National Institutes of Health [7–9]. This 
is a no-cost, web-based software platform for collecting and managing data and 
administering online surveys. Each study site is assigned its own data access group 
and can only see records entered by users within this group.
Participants are entered into the database using their assigned SIDN. Data are 
collected at the following time points, each with its own specifications: baseline 
(pre-RT), during treatment, and follow-up. A total of 1,604 data variables provide 
information on demographics, diagnosis and associated genetic factors, imag-
ing dates and results, all cancer-related treatments, survival outcomes, and all 
treatment-related toxicities. Question formats allow for quantitative and qualitative 
responses and include drop-down boxes, radio buttons, check-boxes (multiple selec-
tions), text with validation (dates, numbers), and text without validation. Branching 
logic streamlines data input by displaying relevant data variables based on prior 
selections. Radiation plans (inclusive of planning scan, contours, and dose files) and 
pertinent diagnostic imaging (e.g. magnetic resonance imaging) are collected and 
managed using MIM Software Inc.’s MIMcloud (Cleveland, OH; [10]), which is a 
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secure internet-based file transfer service. Files that are uploaded to MIMcloud are 
anonymized by SIDN and then stored on a centrally housed server that is maintained 
by the coordinating center.
PedsQL Core Module surveys, added in September, 2015 as a voluntary com-
ponent of the PPCR, collect data on physical, emotional, social, and cognitive 
functioning [11, 12]. Surveys are administered to patients at the beginning and end 
of treatment, and annually thereafter. For patients under five years of age, surveys 
are completed by the parent only. For patients aged 5–18 years, both the parent and 
child complete the surveys. For patients over the age of 18, no parental survey is 
given. REDCap’s survey functionality allows participants to complete the survey 
electronically as well as receive a secure link by email or text to access follow-up 
surveys. This REDCap function directly deposits the patient’s responses into the 
database, thereby obviating the need for manual data entry.
Each site has permission through the consent process to contact their site’s 
participants, families, and home physicians to request outside medical records and 
update the database. This is critical as proton therapy centers are quaternary referral 
centers and the majority of patients return to their home institution for continued 
oncologic care, which makes longitudinal follow up more difficult [13].
2.6 Data safety and monitoring
All data entered into REDCap are monitored for timeliness of submission, 
completeness, and adherence to protocol requirements. Ongoing monitoring 
procedures include: (1) review of all participant consents and study eligibility at 
registration; (2) database review for discrepancies and potential errors; (3) remote 
or on-site monitoring; (4) monthly reports that identify missing data that are vital 
to the integrity and completeness of the dataset and are subject to a higher standard 
of data monitoring.
2.7 Data usage
All institutions have unfettered access to their own data and can use their data for 
operational planning, quality purposes, or research purposes. Data can be extracted 
manually or via REDCap’s built-in reporting features. For use of multi-center data, 
investigators may submit a “Request for Data” (RFD) through a REDCap question-
naire. RFDs are then reviewed by the PPCR coordinating center and each site PI. 
Each PI can decide whether to include their site’s data in the requested project. Data 
are available for investigator-initiated research and for investigators wishing to 
partner with the PPCR to answer questions in pediatric oncology.
3. Data and patient characteristics
This collaborative effort aims to expedite investigations into and understanding 
of pediatric patient survival, treatment toxicity, and impacts on quality of life after 
RT by pooling data from multiple institutions and making them available for study 
to participating investigators. Data are qualitative and quantitative in nature, inclu-
sive of patient demographics, dosimetric statistics of the radiation target and healthy 
tissues, and neoadjuvant and/or adjuvant treatments that are administered as part of 
standard comprehensive cancer care. In addition, dose distribution data are curated, 
which are critical in providing a higher level of granularity in dosimetric studies.
To date, the PPCR has enrolled more than 3,200 patients, with a steady annual 
accrual of about 450 patients in recent years. Notably, the COVID pandemic has 
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slowed accrual in 2020 due to the various institutional responses that put non-COVID 
research on hold to focus attention on the health crisis. Patients have a median age of 
ten years and are mostly residents of the United States (76%), male (57%), White/
Caucasian (71%), and non-Hispanic/Latino (71%) (Table 1, Figure 1, Figure 2). RT 
has been delivered using protons in 99% of participants, reflecting that the bulk of 
institutions that joined were proton centers prior to 2018 when enrollment criteria 
Total (n = 3260)
Characteristics





Black or African American 242 (7.4%)
Arabic/Middle Eastern 35 (1.1%)
Asian 171 (5.2%)
White/Caucasian 2329 (71.4%)
Native American/Alaska Native 16 (0.5%)
Native Hawaiian or Other Pacific Islander 11 (0.3%)




Hispanic or Latino 353 (10.8%)
Not Hispanic or Latino 2305 (70.7%)
Unknown or Not Reported 602 (18.5%)
United States Residencyβ
United States 2461 (75.5%)
Non-United States 542 (16.6%)









αTotals sum >100% due to multiple selections per patient.
βDue to IRB restrictions, patient residency is not reported for some patients.
Table 1. 
Characteristics of PPCR participants.
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became agnostic of radiation modality. Nearly 60% of the tumors treated in this 
cohort originated in the CNS (Table 1, Figure 3), which is the most common site of 
solid tumors in the pediatric population.
Since its inception, the PPCR’s structure and scope have developed and expanded 
to adapt to the ongoing treatment landscape to address this unmet need within pedi-
atric radiation medicine. For instance, in 2018 patients treated with XRT were made 
eligible for enrollment [14]. Incorporation of these data will facilitate photon/proton 
comparison studies that are critical for better understanding the strengths and 
weaknesses of PRT. This is especially true for developing dose constraints for organs 
at risk as these may not be identical across RT modalities. Such is the case for the 
brainstem, whose PRT dose limit was reduced on the most recent COG ependymoma 
protocol (ACNS0831). While the topic is controversial, there is some concern that 
there may be an increased risk of brainstem injury with PRT compared to XRT using 
a typical relative biological effectiveness dose conversion of 1.1 for PRT [15–18].
Figure 1. 
Participant residency by state in the United States.
Figure 2. 
Participant residency by country.
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4. Future objectives
The PPCR has established a centralized, collaborative, and adaptive framework 
for data acquisition in pediatric patients receiving RT, with respect to treatment 
parameters and quality of life. This registry resource is now robustly able to bet-
ter evaluate differences in practice patterns, dosimetric changes, and the clinical 
impacts of the treatments we deliver. The platform we have created is now being 
leveraged by the Epidemiology branch of the NCI to allow for large-scale cohort 
research. Furthermore, the PPCR study staff are also participating in the larger 
effort of the Childhood Cancer Data Initiative [19] recently started to accelerate the 
speed of research with the ultimate goal of improving cancer treatment and out-
comes for pediatric patients.
Looking forward, we aim to continue to expand the network of participating 
institutions not only domestically, but also internationally - first into Canada and 
Australia and then into other countries that allow sharing of de-identified data. 
This will not only serve to continue to amass data for rare tumors for which single-
institution studies are simply not feasible, but will also yield insights into variations 
in practice patterns and which treatment regimens are the most effective and safest. 
In addition, the dynamic nature of the registry facilitates incorporation of data 
from other treatment modalities (e.g. FLASH radiotherapy, other particle therapies, 
etc.), much like how photon-based treatment data have been incorporated recently. 
This will further expand our understanding of how to best manage pediatric 
malignancies by adapting data acquisition to ongoing technologic developments 
and changes in practice patterns. We encourage all to use this resource to improve 
cancer care and outcomes for pediatric cancer patients undergoing treatment as 
well as those who have completed therapy.
Figure 3. 
Histogram showing the ten most-represented histologies in the PPCR. CNS tumors are shown in blue and non-
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